Role of hypertension in coronary artery disease

American Journal of Nephrology

Volumn 16, Issue 3, 1996, Pages 210-216

  Weber, M A ^a,b  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Antihypertensives; Coronary heart disease; Coronary hypothesis; Hemodynamics; Proliferative changes; Risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; HEART HEMODYNAMICS; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

EID: 0029989463     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000169000     Document Type: Article

References (45)

1. MacMahon S, Peto R, Cutler J, Collin R, Sorlic P, Ncalon J, Abbott R, Godwin J, Dyer A, Stamler J: Blood pressure, stroke and coronary heart disease. Part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990:335:765-774.
2. Stamler J, Stamler R, Neaton JO: Blood pressure. systolic and diastolic, and cardiovascular risks. US Population Data. Arch Intern Med 1993:153:598-615.
3. Neutel JM, Smith DHG, Graettinger WF, Weber MA: Heredity and hypertension. Impact on metabolic characteristics. Am Heart J 1992: 124:435-440.
4. Neutel JM, Smith DHG, Graettinger WF, Winer RL, Weber MA: Metabolic characteristics of hypertension. Importance of positive family history. Am Heart J 1993:126:924-929.
5. Williams RR, Hunt SC, Hasstcdt SJ. et al: Current knowledge regarding the genetics of human hypertension. J Hypertens Suppl 1989;7:S8-S13.
6. Ward R: Familial aggregation and genetic epidemiology of blood pressure, in Laragh JH. Brenner BM (cds): Hypertension: Pathophysiology. Diagnosis and Management. New York. Raven Press, vol I, 1990. pp 81-100.
7. Pickering G: Hyperpiesis: High blood pressure without evident cause: essential hypertension. BMJ 1965:2:1021-1025.
8. Caulfield M, Lavender P, Farrall M, M unroe P. et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994:330: 1629-1633.
9. Jcunemaitre X, Soubrier F, Kotelestev YV, et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992:71:19-80.
10. Schunkert H, Hense HW, Holmer SR, Stender M. et al: Association between a deletion polymorphism of the angiotcnsin-converting-en-zyme gene and left ventricular hypertrophy. N Engl J Med 1993:330:1634-1638.
11. Cambien F, Poirier O, Lecerf L. et al. Deletion polymorphism in the gene for angiotensin-con-vorting enzyme is a potent risk factor for myocardial infarction. Nature 1992:359:641-644.
12. Celentano A, Galderisi M, Garofalo M. et al: Blood pressure and cardiac morphology in young children of hypertensive subjects. J Hypertens Suppl 1988:4:S107-S109.
13. Graettinger MF, Neutel JM, Smith DHG, Weber MA: Left ventricular diastolic filling alterations in normotensive young adults with a family history of systemic hypertension. Am J Cardiol 1991:68:51-56.
14. Grunfeld B, Perelstein E, Simsolo R, Gimenez M, Romero JC: Renal functional reserve and microalbuminuria in offspring of hypertensive parents. Hypertension 1990:15:257-261.
15. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991:265:3255-3264.
16. Dahlof B, Lundholm L, Hansson L. et al: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypcrten-sion). Lancet 1991:338:1281-1285.
17. MRC Working Party: Mcdical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992:304:405-412.
18. Deedwania PC, Nelson JR: Pathophysiology of silent myocardial ischemia during daily life. Circulation 1990:82:1296-1304.
19. Ekbom T, Dahlof B, Hansson L, Lindholm L, Oden A, Schersten B, Wester PO: The stroke preventive effect in elderly hypertensives cannot fully be explained by the reduction in office blood pressure insights from the Swedish trial in old patients with hypertension (STOP-Hypertension). Blood Press 1992:1:168-172.
20. Leren P, Foss OP, Helgeland A, Hjermann I, Holme I, Lund-Larsen PG: Effect of propranolol and prazosin on blood lipids. Lancet 1980: ii:4-6.
21. Weidmann P, Uehlinger DE, Gerger A: Antihy-pcrtensive treatment and serum lipoproteins. J Hypertens 1985:3:297-306.
22. Siscovick DS, Rachunathan RE, Psaty BM. et al: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1993:330:1852-1857.
23. Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial's risk factor changes and mortality results. JAMA 1982:248:1465-1477.
24. Pollare T, Lithell H, Seliinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988:31:415-420.
25. Swislocki ALM, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance and hyper-insulinemia in patients with hypertension. Am J Hypertens 1989:2:419-123.
26. Dzau VJ, Gibbons GH, Cooke JP, Omoigui N: Vascular biology and medicine in the 1990s: Scope, concepts, potentials, and perspectives. Circulation 1993:87:705-719.
27. Simon AC, Pithois-Merli I, Levenson J: Physio-pharmacological approach to mechanical factors of hypertension in the atherosclerotic process. J Hum Hypertens 1991:5(Suppl. I):15-21.
28. Powell JS, Clozel JP, Muller RKM, et al: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989:245:186-188.
29. Chobanian AV, Haudenschild CC, Nickerson C, Drago R: Antiatherogenic effect of captopril in the Watanabe heritable hypcrlipidcmic rabbit. Hypertension 1990:15:327-331.
30. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction alter myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992:327:669-677.
31. Cohn JN: The prevention of heart failure: A new agenda. N Engl J Med 1992;327:725-727.
32. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, et al: The effect of angiotcnsin-converting-cn-zyme inhibition on diabetic nephropathy. N Engl J Med 1993:329:1456-1462.
33. Nelson E, Merrill D, Sweet C: Proceedings of the 5th European Meeting on Hypertension. Milan. Italy. 1991, Abstract 512.
34. Nelson E, Arcuri K, Ikcda L, Snavely D, Sweet C: Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 1992:5:19A.
35. Raya TE, Fonken SJ, Lee RW, et al: Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens 1991: 4(Suppl.):334S-340S.
36. Loutzenhiser R, Epstein M, Hayashi K. et al: Characterization of the renal microvascular effects of angiotensin II antagonist. DuP 753: Studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 1991:4(Suppl.):309S-314S.
37. Camargo JF, von Lutterotti N, Pecker MS. et al. DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet. Am J Hypertens 1991;4(Suppl.): 341S-345S.
38. Von Lutterotti N, Camargo JF, Mueller FB. et al. Angiotensin II receptor antagonist markedly reduces mortality in salt-loaded Dahl S rats. Am J Hypertens l991:4(Suppl.):346S-349S.
39. KaulTman RF, Beans JS, Zimmerman KM, Brown RF, Steinberg Ml: Losartan. a nonpeptide angiotensin II (Ang II) receptor antagonist. inhibit neointima formation following balloon injury to rat carotid arteries. Life Sci 1991:49:223-228.
40. Henry PD, Bentley KI: Suppression of athero-genesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 1981:68:136-139.
41. Lichtlen PR, Hugenholtz PG, Rafilenbeaul W. et al: Retardation of angiographic progression of coronary artery disease by nifedipine: Results of the International Nifedipine Trial on Anti-atherosclerotic therapy (INTACT). Lancet 1990:335:1109-1113.
42. Waters D, Lespersancc J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990: 82:1940-1953.
43. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. BMJ 1985:291:97-104.
44. Report by he Management Committee: The Australian therapeutic trial in mild hypertension. Lancet 1980:i:1261-1267.
45. Neaton JD, Grimm RH Jr, Prineas RJ, et al: Treatment of mild hypertension study (TOMHS): final results JAMA 1993;270:713-724